Ebastine in chronic urticaria: A double-blind placebo-controlled study

Abstract

The effect of ebastine 10 mg once daily was studied in a double-blind comparison with placebo in 204 patients with chronic urticaria. Symptom severity, as assessed by both investigator and patient, was significantly reduced by ebastine after 7 and 14 days of treatment. The drug was well tolerated in the majority of patients, with the overall incidence of side-effects not significantly different to that of placebo. It is concluded that ebastine represents an effective and well-tolerated alternative to other non-sedating antihis-tamines in the treatment of chronic urticaria.